Skip to main content
    C

    China SXT Pharmaceuticals Inc (SXTC)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $0.07
    -0.01 (-11.50%)

    Market Cap: $90,520

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    PeriodReportedEst.SurpriseB/MYoY
    Sep 26
    Reported Oct 7
    		$N/AN/AN/ABeat-
    Jun 26
    Reported Jul 1
    		$N/AN/AN/ABeat-
    Sep 25
    Reported Dec 31
    		$-0.05$0.00N/AMiss+75.0%
    Jun 25
    Reported Jul 31
    		$-1.02$0.00N/AMiss-277.8%
    Dec 24
    Reported Mar 28
    		$-1.99$0.00N/AMiss-2090.0%
    Jun 22
    Reported Jul 18
    		$-2.03$0.00N/AMiss-1425.2%
    Dec 21
    Reported Mar 30
    		$-0.20$0.00N/AMiss+52.4%
    Jun 21
    Reported Aug 13
    		$-0.27$0.00N/AMiss-170.0%
    Dec 20
    Reported Mar 30
    		$0.10$0.00N/ABeat+116.8%
    Sep 20
    Reported Dec 31
    		$-0.13$0.00N/AMiss+77.6%
    Jun 20
    Reported Jul 31
    		$-0.42$0.00N/AMiss-700.0%
    Mar 20
    Reported Apr 22
    		$-0.10$0.00N/AMiss+51.6%
    Dec 19
    Reported Mar 30
    		$-0.59$0.00N/AMiss-1288.0%
    Sep 19
    Reported Dec 31
    		$-0.59$0.00N/AMiss-6040.0%
    Jun 19
    Reported Aug 15
    		$0.07$0.00N/ABeat-29.6%
    Mar 19
    Reported Jun 30
    		$-0.21$0.00N/AMiss-616.5%
    Dec 18
    Reported Mar 30
    		$0.05$0.00N/ABeat+38.9%
    Sep 18
    Reported Oct 3
    		$0.01$0.00N/ABeat-87.2%
    Jun 18
    Reported Sep 30
    		$0.10$0.00N/ABeat+27.6%
    Mar 18
    Reported May 7
    		$0.04$0.00N/ABeat-46.7%
    Dec 17
    Reported Mar 30
    		$0.04$0.00N/ABeat-
    Jun 17
    Reported Sep 30
    		$0.08$0.00N/ABeat-
    Mar 17
    Reported Jun 30
    		$0.08$0.00N/ABeat-
    Dec 16
    Reported Mar 31
    		$0.07$0.00N/ABeat-

    Key Metrics

    Valuation
    P/E RatioN/AEV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-153.30%
    ROE-27.50%ROIC-23.34%
    Financial Health
    Debt/Equity0.04xInterest Coverage-27.39x
    Current Ratio7.93xQuick Ratio7.25x
    Trading Statistics
    Beta1.86Avg Volume23.23M
    52-Week High$24000.0052-Week Low$0.06

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.23
    SMA 20$1.90
    SMA 50$2.71
    SMA 200$957.51
    EMA 10$0.96
    EMA 20$2.10
    EMA 50$27.20
    EMA 200$3089.26

    MACD

    Line: -2.67Signal: -3.33Hist: 0.67

    ADX

    ADX: 28.2+DI: 12.4-DI: 5.7

    Aroon & PSAR

    Aroon Up80.0
    Aroon Down100.0
    PSAR$7.82

    Bollinger Bands

    Upper Band$4.09
    Lower Band$-0.30
    %B Position23148%(Upper)
    Band Width0.08

    RSI (14-Day)

    Oversold
    28.2

    Momentum Oscillators

    Stoch %K0.1
    Stoch %D0.2
    Williams %R-99.9
    ROC (10d)-97.7%
    Momentum-2.94
    CCI (20d)-132.6
    MFI (14d)89.9

    Volatility Measures

    ATR (14d)$3.49(5093.1%)
    StdDev (20d)1.10
    Hist Vol633.8%(High)

    Volume Flow

    VWAP$0.07
    OBV945.6M
    AD Line92559.7B
    CMF (20d)-0.381

    Volume Metrics

    Avg Vol (20d)25.5M
    Vol Ratio1.2x
    VWMA (20d)$0.95

    Pivot Points

    R3$0.10
    R2$0.09
    R1$0.09
    Pivot Point$0.08
    S1$0.07
    S2$0.06
    S3$0.05

    Advanced Oscillators

    TSI-43.97
    Ultimate Osc19.0
    KST-497.63

    Financial Data

    QuarterJun 2026Dec 2025Sep 2025Jun 2025Dec 2024Jun 2024Dec 2023Sep 2023Jun 2023Dec 2022Sep 2022Jun 2022
    Total Revenue$1.20M$255,741$626,570$455,709$455,709$414,745$751,073$898,163$469,791$381,696$1.21M$-11,502,270
    Cost of Revenue$364,502$182,251$524,848$339,372$339,372$347,368$361,642$753,992$325,621$213,402$1.12M$4.03M
    Gross Profit$833,974$73,490$101,722$116,337$116,337$67,377$389,431$144,171$144,170$168,294$89,684$-15,530,475
    Operating Expenses$1.62M$465,494$6.44M$1.14M$1.14M$386,511$-3,027,471$4.82M$4.82M$2.40M$1.24M$8.44M
    R&D$0$0$0$0$0$0$0$0$0$0$0$0
    SG&A$686,991$362,713$6.44M$1.02M$1.02M$361,199$3.62M$4.73M$4.73M$2.16M$483,982$2.20M
    Operating Income$-784,008$-392,004$-6,338,925$-1,021,106$-1,021,106$-319,134$3.42M$-4,674,510$-4,674,511$-2,228,532$-1,150,450$1.28M
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$31,640$15,820$31,325$232,875$232,875$91,236$103,880$336,520$92,490$0$384,286$3.56M
    Income Before Tax$-1,210,267$81,858$-6,368,803$-1,250,542$-1,250,542$-401,284$2.79M$-90,728$-4,842,769$-2,220,081$-747,300$2.38M
    Income Tax Expense$-1,373,985$0$0$0$0$-10,921,232$-513,232$4.76M$5,310$0$4$-596,164
    Net Income$163,718$81,858$-6,368,803$-1,250,542$-1,250,542$-401,284$3.30M$-4,848,079$-4,848,079$-2,220,081$-1,494,609$2.32M
    EBITDA$-672,889$-336,445$-6,306,825$-1,007,348$-1,014,227$-240,638$3.72M$-4,571,760$-4,623,136$-1,971,733$-465,257$4.99M
    EBIT$-784,008$-392,005$-6,338,925$-1,021,106$-1,021,106$-319,134$3.63M$-4,674,510$-4,674,511$-2,053,837$-575,223$5.28M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SXTC

    News

    A 9.99% warrant exercise limit accompanies Orca Capital's reported China SXT (SXTC) stake.

    Orca Capital has reported a 9.9% beneficial ownership stake in China SXT Pharmaceuticals (SXTC), holding 1,112,788 Class A ordinary shares. The filing indicates that Orca Capital has sole voting and dispositive power...

    Stock Titan•10/15/26•Neutral

    China SXT Pharmaceuticals Raises $12 Million in October Registered Direct Offering

    China SXT Pharmaceuticals (SXTC) successfully closed a registered direct offering on October 9, 2026, raising $12 million in gross proceeds. The offering involved 8 million units...

    The Globe and Mail•10/11/26•Neutral

    Univest Securities, LLC Announces Closing of $12 Million Registered Direct Offering for its Client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC)

    Univest Securities, LLC announced the closing of a $12 million registered direct offering for its client, China SXT Pharmaceuticals Inc. The offering involved the sale of 8,000,000 Class A ordinary shares at $1.50 per...

    The Manila Times•10/10/26•Somewhat-Bullish

    China SXT Pharmaceuticals Clarifies Warrant Terms in $12 Million Registered Direct Offering

    China SXT Pharmaceuticals Inc. clarified the warrant terms for its $12 million registered direct offering, correcting a typographical error regarding the initial exercise price to $2.75 per Class A share. The offering...

    The Globe and Mail•10/10/26•Neutral

    China SXT Pharmaceuticals closes $12 million registered offering

    China SXT Pharmaceuticals Inc. (NASDAQ:SXTC) has successfully completed a registered direct offering, raising $12 million. The company sold 8 million Class A ordinary shares to institutional investors at $1.50 per share...

    Investing.com•10/10/26•Bullish

    SXTC Valuation and Fair Value

    P/B
    0.0x
    See GNG's fair value

    SXTC Profitability: Margins, ROIC and FCF

    Gross margin
    44.4%
    Operating margin
    -153.3%
    Net margin
    0.0%
    ROIC
    -23.3%
    ROE
    -27.5%
    FCF margin
    -280.9%

    SXTC Competitors

    CompanyTicker
    ProPhase Labs IncPRPH
    NRx Pharmaceuticals IncNRXPW
    Scworx CorpWORX
    Biofrontera Inc. WarrantsBFRIW
    Humacyte IncHUMAW
    Celularity IncCELUW
    Conduit Pharmaceuticals Inc.CDT
    P3 Health Partners IncPIIIW

    Sector: Healthcare

    SXTC Bull Case vs Bear Case

    Bear case

    • SXTC beat EPS estimates in 12.5% of its last 8 reported quarters.
    • SXTC's quarterly revenue changed -43.9% year over year.

    SXTC Earnings: Beat Rate and Next Report

    Beat rate
    1 of 8 quarters (12.5%)

    Frequently Asked Questions About SXTC

    Does SXTC pay dividends?

    China SXT Pharmaceuticals Inc (SXTC) does not currently pay a regular dividend.

    What is SXTC's market cap?

    China SXT Pharmaceuticals Inc (SXTC) has a market capitalization of $90,520 with a current stock price of $0.07.

    Related stocks

    Sector: Healthcare

    All stocks starting with S

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In